Horizon 2020
This sponsor has funded 3 studies across 7 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 31282 | Ongoing | Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER) | No | No |
| 42767 | Ongoing | The European HBV Registry: A joint initiative of TherVacB and DZIF (HBV Registry) | No | No |
| 108254 | Finalised | Clinical validation study of a CAD system with artificial intelligence algorithms for early non-invasive detection of in vivo cutaneous melanoma.... | Yes | Yes |
PAS by Risk Management Plan (RMP) requirement
Horizon 2020
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Horizon 2020
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Horizon 2020
7 Study countries specified are the following:
- Germany
- Ireland
- Italy
- Norway
- Spain
- Sweden
- United Kingdom